InMed Pharmaceuticals (INM) Non-Current Deferred Tax Liability (2022 - 2025)

InMed Pharmaceuticals has reported Non-Current Deferred Tax Liability for 3 years, with the latest figure at $20000.0 in Q2 2025.

• For the quarter ending Q2 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $20000.0; the trailing twelve-month figure through Jun 2025 stood at $20000.0 (changed N/A YoY), and the FY2025 full-year result was $20000.0, changed N/A from the prior year.
• Non-Current Deferred Tax Liability for Q2 2025 stood at $20000.0, down from $211266.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $211266.0 in Q2 2023, with the low at $20000.0 in Q2 2025.
• Historically, Non-Current Deferred Tax Liability has averaged $101024.0 across 3 years, with a median of $71806.0 in 2022.
• The largest YoY upside for Non-Current Deferred Tax Liability was 194.22% in 2023 against a maximum downside of 194.22% in 2023.
• InMed Pharmaceuticals' Non-Current Deferred Tax Liability stood at $71806.0 in 2022, then soared by 194.22% to $211266.0 in 2023, then sank by 90.53% to $20000.0 in 2025.
• The last three Non-Current Deferred Tax Liability figures came in at $20000.0 (Q2 2025), $211266.0 (Q2 2023), and $71806.0 (Q2 2022), per Business Quant data.